Osteoporosis Treatment in Chronic Kidney Disease

Introduction to Denosumab Therapy

The American College of Cardiology is not applicable here, however, the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend denosumab as a treatment option for patients with chronic kidney disease (CKD) and low bone mineral density, with intensive calcium monitoring and supplementation protocols mandatory 1, 2

Denosumab is preferred over teriparatide in CKD stages 3a-5 due to its lack of requirement for dose adjustment for renal function, unlike bisphosphonates which are contraindicated when eGFR <30 mL/min 1
Teriparatide use in CKD G4-G5 is off-label with no established safety or efficacy data, and there are no published studies of teriparatide in dialysis patients with secondary hyperparathyroidism 3

Evaluation for CKD-mineral and bone disorder (CKD-MBD) by measuring intact parathyroid hormone (iPTH), serum calcium, 25(OH) vitamin D, and 1,25(OH)₂ vitamin D if eGFR <30 mL/min/1.73 m² is necessary before initiating denosumab 1
Consideration of bone biopsy to accurately diagnose the underlying bone phenotype is recommended, as antiresorptives like denosumab can exacerbate low bone turnover states 4, 5, 6, 1

All patients receiving denosumab must take calcium 1,000 mg daily and vitamin D at least 400 IU daily, with biologically active vitamin D (calcitriol, paricalcitol, or doxercalciferol) required for patients with eGFR <30 mL/min/1.73 m² 1, 2

Serum calcium and phosphorus must be checked at least monthly for the first 3 months, then every 3 months thereafter, and PTH levels must be monitored at least every 3 months for the first 6 months, then every 3 months 1
Pre-dose monitoring of serum calcium before each denosumab injection is necessary 2

The incidence of hypocalcemia in patients with advanced CKD reaches 25.5% with denosumab, with severe symptomatic hypocalcemia typically occurring 4-35 days after administration 2
Treatment decisions must account for the magnitude and reversibility of biochemical abnormalities (calcium, phosphate, PTH) 5, 1

Denosumab should not be stopped abruptly due to its reversible mechanism of action, and baseline dental evaluation is mandatory before initiating therapy to prevent osteonecrosis of the jaw 2
The 2017 KDIGO CKD-MBD guidelines provide the highest-quality guidance for this population, specifically addressing treatment of bone abnormalities in CKD G3a-G5D 4, 5, 6
The 2023 American College of Rheumatology (ACR) glucocorticoid-induced osteoporosis guideline conditionally recommends treatment with oral or IV bisphosphonates, denosumab, or PTH/PTHrP based on individual patient factors in solid organ transplant recipients with GFR ≥35 mL/min, but notes these recommendations are based on low-quality evidence 7, 8